概要
Regulations and industry bodies are joining hands to simplify the process of drug development. But trials are becoming increasingly complex and the costs of drug development are increasing every day.
In this increasingly complex world, medical writers are striving to navigate their way through complex safety and regulatory documents and are leveraging technology and RWE to drive expedited submissions.
プログラム委員会
-
Nimita Limaye, PHD Research VP, Life Sciences R&D Strategy and Technology, at IDC
IDC, United States -
Bindu Narang Executive Director - Patient Safety Solutions
Labcorp, India -
Ashwini Patil Expert Scientific Writer
Novartis Healthcare Pvt. Ltd., India -
Rajesh Kher, PHD Head of Outsourcing Partnership Management in the Capabilities group of IDAR
Janssen and Janssen Pharmaceutical Research & Development, L.L.C., India -
Sofia Baig Practice Lead - HEOR, PRMA & RWE
Tata Consultancy Services, India
